Pcn142 Lifetime Indirect Costs Associated With Multiple Myeloma: Analysis of the Model Patient in Single Eu Jurisdiction in 2018

Abstract

Insurance Company (V seobecná zdravotná pois tovna, V sZP). We used the "bottomup" approach that helped us identify, quantify and value resources in a disaggregated way, so that each element of the cost was estimated individually and they were summed up at the end, similarly to our first research conducted previously. We calculated real direct costs for the model patient with MM from the diagnosis to death. Results: Based on internal cost resources provided upon request from V sZP, we identified real direct costs associated with MM from the diagnosis till death (% from total direct costs,